Goldman Sachs initiated coverage of Genscript Biotech with a Buy rating and HK$29.34 price target, implying 31% upside from current levels. The analyst says cell and gene therapies are seeing expanded adoption which could drive up the market potential. The company demonstrates potential solutions that could be critical in driving more explosive growth of cell and gene therapies particularly autologous cell therapies, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>